CR7804A - COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME - Google Patents
COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROMEInfo
- Publication number
- CR7804A CR7804A CR7804A CR7804A CR7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- syndrome
- myelodisplasic
- acute leukemia
- combined therapy
- Prior art date
Links
Classifications
-
- E—FIXED CONSTRUCTIONS
- E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
- E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
- E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
- E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
- E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
- E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- E—FIXED CONSTRUCTIONS
- E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
- E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
- E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan metodos de tratamiento y combinaciones farmaceuticas para el tratamiento de la leucemia aguda, tales como leucemia mielogenosa aguda y sindrome displasico. Los metodos de tratamiento y combinaciones farmaceuticas emplean un conjugado citotoixico de anti-CD33 en comnbinacion con la menos un compuesto seleccionado del grupo que consiste de una antraciclina y un analogo del nucleosido de primidina o purina.Treatment methods and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia and dysplasic syndrome. The treatment methods and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a primidin or purine nucleoside analog.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2002/035532 WO2004043461A1 (en) | 2002-11-06 | 2002-11-06 | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
CR7804A true CR7804A (en) | 2008-10-29 |
Family
ID=32311637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR7804A CR7804A (en) | 2002-11-06 | 2005-04-25 | COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1575582A4 (en) |
JP (1) | JP2006508119A (en) |
CN (1) | CN1720044A (en) |
AU (2) | AU2002348178A1 (en) |
BR (1) | BR0215935A (en) |
CA (1) | CA2504611A1 (en) |
CR (1) | CR7804A (en) |
MX (1) | MXPA05004711A (en) |
NO (1) | NO20052009L (en) |
WO (1) | WO2004043461A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7977320B2 (en) | 2004-10-29 | 2011-07-12 | The Regents Of The University Of California | Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents |
EP1661584A1 (en) * | 2004-11-26 | 2006-05-31 | Heinz Dr. Faulstich | Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy |
CA2614321A1 (en) * | 2005-07-06 | 2007-01-18 | Kanisa Pharmaceuticals, Inc. | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |
ATE521366T1 (en) * | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | APPLICATION OF AMATOXIN CONJUGATES AND PHALLOTOXIN CONJUGATES WITH MACROMOLECLES FOR CANCER THERAPY AND THERAPY OF INFLAMMATION |
CN1994293A (en) * | 2006-08-18 | 2007-07-11 | 上海交通大学医学院附属瑞金医院 | Application of oridonin in pharmacy |
EP2084527A4 (en) * | 2006-11-02 | 2011-07-27 | Seattle Genetics Inc | Methods of treating neoplastic, autoimmune and inflammatory diseases |
HRP20220428T3 (en) * | 2007-02-16 | 2022-05-27 | Rotalec Ip Holdings Llc | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
EP2649997B1 (en) * | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
WO2010024374A1 (en) | 2008-08-29 | 2010-03-04 | 学校法人北里研究所 | Method for detecting the drug effects of dna methylation-inhibitors |
EP3442584B1 (en) | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
EP3463463A4 (en) | 2016-06-03 | 2020-01-15 | Seattle Genetics, Inc. | Combination of cd33 antibody drug conjugates with chemotherapeutic agents |
US11191771B2 (en) | 2016-06-09 | 2021-12-07 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors |
GEP20227357B (en) * | 2017-06-22 | 2022-02-25 | Servier Lab | Combination of mcl-1 inhibitor and standard of care treatment for hematologic cancers, uses and associated pharmaceutical compositions |
CN110869029A (en) * | 2017-07-09 | 2020-03-06 | 拜欧赛特有限公司 | Combination cancer therapy |
CN113631193A (en) * | 2019-01-28 | 2021-11-09 | 德州大学系统董事会 | Metal chelator combination therapy for the treatment of cancer |
CN110123825B (en) * | 2019-05-28 | 2021-11-30 | 宁波市鄞州人民医院 | Pharmaceutical composition containing demethoxydaunorubicin |
IL302252A (en) * | 2020-10-27 | 2023-06-01 | Vor Biopharma Inc | Compositions and methods for treating hematopoietic malignancy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
CN1468259A (en) * | 2000-08-08 | 2004-01-14 | ͨ��ҽ�ƹ�˾ | Immunotherapy for chronic myelocytic leukemia |
-
2002
- 2002-11-06 EP EP02784400A patent/EP1575582A4/en not_active Withdrawn
- 2002-11-06 MX MXPA05004711A patent/MXPA05004711A/en active IP Right Grant
- 2002-11-06 CN CNA028301404A patent/CN1720044A/en active Pending
- 2002-11-06 BR BR0215935-0A patent/BR0215935A/en not_active IP Right Cessation
- 2002-11-06 JP JP2004551359A patent/JP2006508119A/en active Pending
- 2002-11-06 AU AU2002348178A patent/AU2002348178A1/en not_active Abandoned
- 2002-11-06 WO PCT/US2002/035532 patent/WO2004043461A1/en active Application Filing
- 2002-11-06 CA CA002504611A patent/CA2504611A1/en not_active Abandoned
-
2005
- 2005-04-25 CR CR7804A patent/CR7804A/en not_active Application Discontinuation
- 2005-04-25 NO NO20052009A patent/NO20052009L/en not_active Application Discontinuation
-
2010
- 2010-03-22 AU AU2010201113A patent/AU2010201113A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2010201113A1 (en) | 2010-04-15 |
BR0215935A (en) | 2005-08-09 |
AU2002348178A1 (en) | 2004-06-03 |
JP2006508119A (en) | 2006-03-09 |
CA2504611A1 (en) | 2004-05-27 |
NO20052009D0 (en) | 2005-04-25 |
EP1575582A4 (en) | 2009-03-11 |
CN1720044A (en) | 2006-01-11 |
NO20052009L (en) | 2005-06-27 |
MXPA05004711A (en) | 2005-08-03 |
EP1575582A1 (en) | 2005-09-21 |
WO2004043461A1 (en) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR7804A (en) | COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME | |
AR027355A1 (en) | THIAZOLIDINCARBOXILIC ACIDS | |
ECSP105178A (en) | ARIL UREA COMPOUNDS IN COMBINATION WITH OTHER CITTATIC OR CYTOTOXIC AGENTS FOR CANCER TREATMENT IN HUMANS | |
CL2008002139A1 (en) | Dimer compounds derived from pyrrolo [2,1c] [1,4] benzodiazepine-5 -one (tomaimycin), a conjugate comprising them; procedure of preparation of conjugates; pharmaceutical composition comprising the compounds or conjugates; and use of compounds and conjugates in the treatment of cancer. | |
UY29868A1 (en) | NUCLEOCIDOS 4 MODIFIED AS ANTIVIRAL AGENTS | |
CR8146A (en) | METHODS TO TREAT CANCERES USING 3- (4-AMINO -1-OXO-1,3 DIHIDRO-ISOINDOL-2-IL) POLYPORMAL FORMS - PIPERIDINA-2,6-DIONE | |
CL2007002994A1 (en) | HETEROCICLIC DERIVATIVE COMPOUNDS CONTAINING SULFAMOIL, INHIBITORS OF HSP90; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER, SUCH AS CANCER OF BREAST, COLON AND PROSTATE, BETWEEN OTHERS. | |
CL2008002224A1 (en) | Pharmaceutical composition comprising a) a compound selected from paclitaxel, docetaxel, ispinesib, thiazoloquinoline, among others, and b) aurora kinase inhibitor compounds selected from imidazopyrazine derivatives; use of combination and composition to treat cancer. | |
CL2009001170A1 (en) | Pharmaceutical composition for oral administration comprising immediate release 5-azacitidine without enteric coating; and its use for the treatment of a disease associated with abnormal cell proliferation, such as myelodysplastic syndrome, acute myelogenous leukemia and lung cancer, among others. | |
AR013269A1 (en) | PRODUCT CONTAINING AT LEAST A DOUBLE FILAMENT RNA COMBINED WITH AT LEAST AN ANTI-VIRAL AGENT, FOR THERAPEUTIC USE IN THE TREATMENT OF A VIRAL DISEASE, ESPECIALLY OF VIRAL HEPATITIS | |
CR9846A (en) | 2-AMINO-7,8-DIHIDRO-6H-PIRIDO [4,3-D] PIRIMIDINA-5-ONAS | |
WO2004087713A8 (en) | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases | |
MX368013B (en) | Cancer treatment. | |
CR6404A (en) | USEFUL REPLACED BICYCLE DERIVATIVES AS AGENTS AGAINST CANCER | |
UY29796A1 (en) | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | |
WO2008101214A3 (en) | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders | |
MX2021015993A (en) | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome. | |
AR023616A1 (en) | COMBINED PREPARATIONS UNDERSTANDING ANTHRACICLINE DERIVATIVES | |
AR112103A1 (en) | COMPOUNDS FOR THE TREATMENT OF TNBC | |
WO2005076888A3 (en) | Anti-cancer therapies | |
HRPK20041072B3 (en) | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer | |
SV2009003403A (en) | EXTRUDED WITH IMPROVED FLAVOR MASK | |
AR032989A1 (en) | A PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF CANCER | |
SV2008002856A (en) | 2-AMINO-7, 8-DIHIDRO-6H-PIRIDO [4,3-D] PIRIMIDINA-5-ONAS | |
AR067420A1 (en) | ANTITUMORAL COMBINATIONS CONTAINING AN INHIBITING AGENT OF THE ENDOTELIAL VASCULAR GROWTH FACTOR (VEGF) AND IRINOTECAN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |